Lymphoma: Pathology, Diagnosis and TreatmentRobert Marcus, John W. Sweetenham, Michael E. Williams Major advances have occurred in almost every aspect of the diagnosis and treatment of lymphoma in recent years. Our understanding of the molecular biology and genetics of the disease has increased exponentially, and significant developments in imaging of this malignancy have resulted in earlier and more accurate diagnosis. At the same time, advances in therapeutic immunology have led to the development of several new treatment options. This landmark new text describes these advances in a single concise volume, placing them in the context of daily clinical practice. Introductory chapters review epidemiology, prognostic factors, imaging and therapeutic immunology. These are followed by chapters on each lymphoma subtype, dealing comprehensively with all aspects of the diagnosis and treatment of the disorder. Highly illustrated in full colour throughout and written and edited by the leading authorities in the field, this book provides all the information needed to diagnose and manage these complex disorders. |
Contents
II | 3 |
III | 12 |
IV | 19 |
V | 32 |
VI | 55 |
VII | 68 |
VIII | 87 |
IX | 89 |
XII | 141 |
XIII | 154 |
XIV | 168 |
XV | 182 |
XVI | 200 |
XVII | 215 |
XVIII | 233 |
XIX | 252 |
Other editions - View all
Lymphoma: Pathology, Diagnosis, and Treatment Robert Marcus,John W. Sweetenham,Michael E. Williams Limited preview - 2013 |
Lymphoma: Pathology, Diagnosis, and Treatment Robert Marcus,John W. Sweetenham,Michael E. Williams Limited preview - 2013 |
Common terms and phrases
ABVD activity aggressive ALCL alemtuzumab allogeneic antigens approach ASCT associated B-cell lymphoma biopsy Blood bone-marrow Burkitt's lymphoma Cancer chemotherapy CHOP chromosomal Clin clinical trials combination complete response cyclophosphamide cytogenetics cytoplasm demonstrated diagnosis diffuse large B-cell disease DLBCL dose doxorubicin early-stage efficacy etoposide evaluated extranodal FDG-PET first-line fludarabine follicular lymphoma genetic high-dose histological Hodgkin's lymphoma idiotype immune response Immunophenotypically infection infiltrate initial involvement large B-cell lymphoma lesions leukemia lymph node lymphocytes lymphoid malignancies MALT lymphoma mantle cell lymphoma marrow molecular monoclonal antibodies nodal non-Hodgkin's lymphoma Oncol outcome overall survival Pathology patients with relapsed PCNSL phase phoma prednisone Primary cutaneous prognostic factors progression-free proliferation protein PTLD radioimmunotherapy radiotherapy randomized refractory regimen remission reported response rates risk rituximab stage stem-cell transplantation strategies studies subtypes Table target therapeutic therapy tion tissue toxicity translocation treated treatment tumor cells vaccine vincristine